CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy

Journal of Digestive Diseases

Volumn 9, Issue 2, 2008, Pages 79-83

  Ma, Juan ^a   Yang, Xiu Yan ^a   Qiao, Liang ^b   Liang, Liu Qin ^a   Chen, Min Hu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

2; 3; CYP2C9; CYP2C9 genotype; Non steroidal anti inflammatory drugs; NSAID induced gastropathy

Indexed keywords

ACEMETACIN; CELECOXIB; CYTOCHROME P450 2C9; DICLOFENAC; IBUPROFEN; INDOMETACIN; LORNOXICAM; LOXOPROFEN; MELOXICAM; NABUMETONE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; AGED; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; BLOOD ANALYSIS; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG METABOLISM; DYSPEPSIA; FEMALE; GASTROSCOPY; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOSITIS; OCCULT BLOOD; PEPTIC ULCER BLEEDING; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; STOMACH DISEASE; STOMACH EROSION; STOMACH ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; CHILD; CHINA; FEMALE; GASTROINTESTINAL DISEASES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC;

EID: 42449136588     PISSN: 17512972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2008.00326.x     Document Type: Article

References (21)

1. Edelson JT, Tosteson ANA, Sax P. Cost-effectiveness of misoprostol for prophylaxis against non-steroidal anti-inflammatory drug-induced gastrointestinal bleeding. JAMA 1990; 264: 41-4.
2. Roth SH. Non-steroidal anti-inflammatory drug gastropathy. We start it, can we stop it? Arch Intern Med 1986; 146: 1075-6.
3. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic non-steroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82: 1153-8.
4. Whittle BJ, Higgs GA, Eakins KE, Moncada S, Vane JR. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 1980; 84: 271-3.
5. Miners JO, Birkett DJ. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-8.
6. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-63.
7. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: Ethnic distribution and functional significance. Advanced Drug Delivery Rev 2002; 54: 1257-70.
8. Taube J, Halsall D, Baglin T. Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-19.
9. Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 2005; 45: 477-94.
10. Wang SL, Huang JD, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5: 37-42.
11. Martin JH, Begg EJ, Kennedy MA, Roberts R, Barclay ML. Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? Br J Clin Pharmacol 2001; 51: 627-30.
12. Laine L. Approaches to non-steroidal anti-inflammatory drug use in the high risk patient. Gastroenterology 2001; 120: 594-606.
13. Hollenz M, Stolte M, Leodolter A, Labenz J. NSAID-associated dyspepsia and ulcers: A prospective cohort study in primary care. Dig Dis 2006; 24: 189-94.
14. Martinez C, Blanco G, Ladero JM et al. Genetic predisposition to acute gastrointestinal bleeding after NSAID use. Br J Pharmacol 2004; 141: 205-8.
15. Yang JQ, Morin S, Verstuyft C et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol 2003; 17: 373-6.
16. Si DY, Guo YJ, Zhang YF, Yang L, Zhou H, Zhong DF. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004; 14: 465-9.
17. Guo Y, Zhang Y, Wang Y et al. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in human. Drug Metab Dispos 2005; 33: 749-53.
18. Leung AY, Chow HC, Kwong YL et al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 2001; 98: 2584-7.
19. Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmoller J. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 2002; 72: 62-75.
20. Aithal GP, Day CP, Leathart JB, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10: 511-8.
21. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmõller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: No relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 2003; 55: 51-61.